Lifecycle model-based evaluation of infant 4CMenB vaccination in the UK

J. P. Sevilla,Daniel Tortorice,David Kantor,John Regan,Kinga H. Meszaros,Ekkehard C. Beck,Najida Begum,David E. Bloom
DOI: https://doi.org/10.1007/s10198-023-01654-y
2024-01-07
The European Journal of Health Economics
Abstract:Invasive meningococcal disease, an uncommon but severe disease, imposes catastrophic health and economic burdens. Cost–utility analysis (CUA) assumes separability in lifetime health and economic variables and cannot capture the full value of preventing such burdens. We overcome these limitations with a retrospective societal perspective cost–benefit analysis (CBA) of meningococcal serogroup B vaccination (4CMenB) of one infant cohort in the United Kingdom using a health-augmented lifecycle model (HALM) incorporating health's interactions with consumption, earnings, non-market time and financial risk.
health policy & services,economics
What problem does this paper attempt to address?